stsg-0002
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 25, 2023 (NCT05760781)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Major surface antigenINHIBITOR
S inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05760703 | Phase 2 | Apr 25, 2023 | Government of China, Peking University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05760781 | Phase 2 | Apr 25, 2023 | Government of China, Peking University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 0 | 1 | 2023 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Staidson (Beijing) Biopharmaceuticals Co., Ltd | For profit | 2 | 2 | 1 | 2023 |
3 organizations
Page 1 / 1